# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $170 price...
BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $170 price...
Piper Sandler analyst Biren Amin initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight rating and annou...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added ...
Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Mon...
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recen...